Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 151,300 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 151,300 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $94.71, for a total value of $14,329,623.00. Following the completion of the transaction, the chief executive officer owned 774,500 shares of the company’s stock, valued at $73,352,895. The trade was a 16.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 6.2%

Shares of KNSA stock opened at $93.86 on Friday. The firm has a market capitalization of $7.32 billion, a P/E ratio of 72.20 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The firm’s fifty day moving average price is $80.46 and its two-hundred day moving average price is $61.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the subject of several recent research reports. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. upped their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average target price of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after purchasing an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA raised its position in shares of Kiniksa Pharmaceuticals International by 41.3% in the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after purchasing an additional 251,578 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after purchasing an additional 128,417 shares during the last quarter. Spruce Street Capital LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after purchasing an additional 326,081 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.